{"id":6296,"date":"2019-10-31T15:58:57","date_gmt":"2019-10-31T10:28:57","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=6296"},"modified":"2021-07-24T12:57:37","modified_gmt":"2021-07-24T07:27:37","slug":"recent-pharma-happenings-for-astellas-pandion-astrazeneca-pear-ironwood","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-astellas-pandion-astrazeneca-pear-ironwood","title":{"rendered":"AZ sells EU rights for Schizophrenia to Cheplapharm; Astellas, Pandion unite to extract the potential of immunomodulation; Pear therapeutics on a journey to develop digital GI treatments with Ironwood"},"content":{"rendered":"\n

AstraZeneca has announced the licensing-out of two\nof its drugs Seroquel and Seroquel XR in Europe and Russia to Cheplapharm\nArzneimittel GmbH. <\/strong><\/h4>\n\n\n\n

According to the deal signed between the companies,\nAZ will receive an upfront payment of USD 178 Million, in addition to other payments\nupon achieving sales milestones. <\/p>\n\n\n\n

The patents of the drug variants Seroquel and\nSeroquel XR are soon expiring in Europe and Russia. However, the company will\ncontinue to manufacture and provide the drugs, primarily used to treat\nschizophrenia and bipolar disorder, to Cheplapharm during the transition\nperiod. <\/p>\n\n\n\n

According to a published paper by McGrath J, Saha S, Chant D, Welham J, the Schizophrenia <\/strong><\/a>incidence was estimated to be around 1.5 per 10,000 people. <\/p>\n\n\n\n

Pandion Therapeutics has collaborated with Astellas Pharma to advance R&D and commercialize immunomodulators for the treatment of auto-immune diseases of the pancreas and other drugs for Type-1 diabetes. <\/strong><\/h4>\n\n\n\n

Under the terms of the agreement, Pandion will\nbe responsible for the design and discovery of bispecific drugs through Pandion’s\nproprietary modular immune effector and tissue tether platform. <\/p>\n\n\n\n

The deal could yield nearly USD 45 Million to\nPandion upfront and more than USD 750 Million as milestone development and\ncommercial payments. Moreover, the company might also receive royalties on sales\nof commercial products worldwide. On the other hand, Astellas will be in\nauthority of conducting preclinical, clinical and commercialization of the drug\ncandidates.  <\/p>\n\n\n\n

The companies\u2019 main focus will be on treating Type-1 diabetes which results in deterioration of pancreas. Other autoimmune diseases that the collaboration will be working on are Systemic lupus erythematosus<\/a> and rheumatoid arthritis.<\/a> <\/p>\n\n\n\n

Pear therapeutics and Ironwood Pharmaceuticals\nhave collaborated to gauge the Prescription Digital Therapeutics (PDTs) for the\ntreatment of selected Gastrointestinal (GI) diseases. <\/strong><\/h4>\n\n\n\n

GI diseases are one of the Pear\u2019s therapeutic areas and so far, the products for substance use disorder and opioid use disorder in the market. Through this agreement, the company is trying to increase its horizon of the pipeline beyond central nervous disorders. <\/p>\n\n\n\n

Moreover, Ironwood\u2019s marketed candidate Linzess (linaclotide), which it markets with Allergan and will soon be acquired by AbbVie for USD63 Billion. The drug is indicated for irritable bowel syndrome <\/a>and chronic idiopathic constipation<\/a>. <\/p>\n","protected":false},"excerpt":{"rendered":"

AstraZeneca has announced the licensing-out of two of its drugs Seroquel and Seroquel XR in Europe and Russia to Cheplapharm Arzneimittel GmbH. According to the deal signed between the companies, AZ will receive an upfront payment of USD 178 Million, in addition to other payments upon achieving sales milestones. The patents of the drug variants […]<\/p>\n","protected":false},"author":1,"featured_media":6298,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[684,349,639,5789,1519],"industry":[17225],"therapeutic_areas":[17229,17239,17227],"class_list":["post-6296","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-astellas","tag-latest-pharma-news","tag-pharma-news","tag-recent-pharma-news","tag-schizophrenia","industry-pharmaceutical","therapeutic_areas-central-nervous-system","therapeutic_areas-gastroenterology","therapeutic_areas-immunological-and-autoimmune-disorders"],"acf":[],"yoast_head":"\nAZ's Cheplapharm; Pandion & Astellas's collaboration; Pear's Agreement<\/title>\n<meta name=\"description\" content=\"Pandion Therapeutics, Astellas Pharma to advance R&D and commercialize immunomodulators for the treatment of auto-immune diseases of the pancreas...\ufeff\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-astellas-pandion-astrazeneca-pear-ironwood\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AZ's Cheplapharm; Pandion & Astellas's collaboration; Pear's Agreement\" \/>\n<meta property=\"og:description\" content=\"Pandion Therapeutics, Astellas Pharma to advance R&D and commercialize immunomodulators for the treatment of auto-immune diseases of the pancreas...\ufeff\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-astellas-pandion-astrazeneca-pear-ironwood\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-10-31T10:28:57+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/10\/09022447\/News_31.10.2019.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AZ's Cheplapharm; Pandion & Astellas's collaboration; Pear's Agreement","description":"Pandion Therapeutics, Astellas Pharma to advance R&D and commercialize immunomodulators for the treatment of auto-immune diseases of the pancreas...\ufeff","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-astellas-pandion-astrazeneca-pear-ironwood","og_locale":"en_US","og_type":"article","og_title":"AZ's Cheplapharm; Pandion & Astellas's collaboration; Pear's Agreement","og_description":"Pandion Therapeutics, Astellas Pharma to advance R&D and commercialize immunomodulators for the treatment of auto-immune diseases of the pancreas...\ufeff","og_url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-astellas-pandion-astrazeneca-pear-ironwood","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2019-10-31T10:28:57+00:00","article_modified_time":"2021-07-24T07:27:37+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/10\/09022447\/News_31.10.2019.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-astellas-pandion-astrazeneca-pear-ironwood","url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-astellas-pandion-astrazeneca-pear-ironwood","name":"AZ's Cheplapharm; Pandion & Astellas's collaboration; Pear's Agreement","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-astellas-pandion-astrazeneca-pear-ironwood#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-astellas-pandion-astrazeneca-pear-ironwood#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/10\/09022447\/News_31.10.2019.jpg","datePublished":"2019-10-31T10:28:57+00:00","dateModified":"2021-07-24T07:27:37+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Pandion Therapeutics, Astellas Pharma to advance R&D and commercialize immunomodulators for the treatment of auto-immune diseases of the pancreas...\ufeff","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-astellas-pandion-astrazeneca-pear-ironwood"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-astellas-pandion-astrazeneca-pear-ironwood#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/10\/09022447\/News_31.10.2019.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/10\/09022447\/News_31.10.2019.jpg","width":772,"height":482,"caption":"Pharma News"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/10\/09022447\/News_31.10.2019-300x187.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Astellas<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">recent pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">schizophrenia<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Astellas<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">recent pharma news<\/span>","<span class=\"advgb-post-tax-term\">schizophrenia<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Oct 31, 2019","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Oct 31, 2019 3:58 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"Pharma News","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/6296","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=6296"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/6296\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/6298"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=6296"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=6296"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=6296"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=6296"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=6296"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}